Filing Flows › Recursion Pharmaceuticals (RXRX) › Q1 2026
Recursion Pharmaceuticals (RXRX) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 6, 2026
Recursion Pharmaceuticals (RXRX) reported revenue of $6.5M for the first quarter 2026 (Q1 2026), -56% from a year earlier and -82% from the quarter before.
Recursion Pharmaceuticals, Q1 2026: revenue $6.5M (-56% year over year), net loss $118M, operating cash flow −$81.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6.5M | -82% | -56% |
| Operating profit | −$129M | — | — |
| Net earnings | −$118M | — | — |
| Operating cash flow | −$81.1M | — | — |
What changed
Revenue was $6.5M in Q1 2026, down 56% year over year and down 82% from the previous quarter. Operating revenue was the largest line at 97% of revenue. Operating revenue lost $8.5M year over year (down 57%), 103% of the total change.
Operating costs exceeded revenue by $128.5M, an operating margin of -1985.6%. Total costs fell 35% while revenue fell 56%. The quarter ended with a net loss of $117.5M, wider than the previous quarter's $108.1M loss.
Operating cash flow was −$81.1M. Non-cash charges added back $19.7M of depreciation and amortization and $22.2M of share-based compensation. Working capital and other items used $5.5M. Capital expenditures of $258K exceeded it, leaving free cash flow of −$81.4M.
Questions
What was Recursion Pharmaceuticals' revenue in the first quarter 2026?
Recursion Pharmaceuticals (RXRX) reported revenue of $6.5M for the first quarter 2026 (Q1 2026), -56% from a year earlier and -82% from the quarter before.